1049-急性髓系白血病细胞亚型对维奈克拉的耐药机制与治疗靶点 episode artwork

EPISODE · May 29, 2026 · 21 MIN

1049-急性髓系白血病细胞亚型对维奈克拉的耐药机制与治疗靶点

from 聊聊Sci

这份研究揭示了急性髓系白血病(AML)中白血病干细胞(LSC)的异质性,并识别出四种决定治疗效果的独特亚型。研究发现,LAMP5+ 单核/树突状(MoDe)干细胞通过依赖 MCL-1 蛋白对常规的 venetoclax 疗法产生抗药性,但此类患者对 MEK1/2 抑制剂表现出特有的敏感性。同时,大多数复发病例是因为白血病干细胞向巨核/红系(MEP)状态转化,从而将生存依赖从 BCL-2 转向了 BCL-xL。通过监测这些特定亚型的生物标志物,医生可以更精准地识别耐药风险并制定个性化的靶向治疗方案。这项工作为克服临床中常见的化疗和靶向药耐药问题提供了重要的分子框架和治疗新路径。References:Waclawiczek A, Leppä A M, Renders S, et al. Leukemic stem cell subtypes determine venetoclax resistance and therapeutic vulnerabilities in AML[J]. Cell Stem Cell, 2026.前往小宇宙评论区与主播互动

Episode metadata supplied by the publisher feed · Published May 29, 2026

Embed this episode

Ready to play

1049-急性髓系白血病细胞亚型对维奈克拉的耐药机制与治疗靶点

0:00 21:07

No transcript for this episode yet

We transcribe on demand. Request one and we'll notify you when it's ready — usually under 10 minutes.

No similar episodes found.

Frequently Asked Questions

How long is this episode of 聊聊Sci?

This episode is 21 minutes long.

When was this 聊聊Sci episode published?

This episode was published on May 29, 2026.

Can I download this 聊聊Sci episode?

Yes. Use the download control on the episode player to save the publisher-provided media file.
URL copied to clipboard!